Novartis Prexige NDA Re-Submission Expected In 2006; TARGET Data “Clean”

Novartis expects to re-submit an NDA for the COX-2 inhibitor Prexige by early 2006 following the completion of several studies requested by FDA in a "not approvable" letter

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet